Cabaletta Bio (CABA) Competitors $1.88 -0.04 (-2.08%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$1.92 +0.05 (+2.39%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. CGC, ALLO, LFCR, AVIR, ATXS, FHTX, GOSS, SLRN, AVTE, and CADLShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Canopy Growth (CGC), Allogene Therapeutics (ALLO), Lifecore Biomedical (LFCR), Atea Pharmaceuticals (AVIR), Astria Therapeutics (ATXS), Foghorn Therapeutics (FHTX), Gossamer Bio (GOSS), Acelyrin (SLRN), Aerovate Therapeutics (AVTE), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Canopy Growth Allogene Therapeutics Lifecore Biomedical Atea Pharmaceuticals Astria Therapeutics Foghorn Therapeutics Gossamer Bio Acelyrin Aerovate Therapeutics Candel Therapeutics Cabaletta Bio (NASDAQ:CABA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Is CABA or CGC more profitable? Cabaletta Bio has a net margin of 0.00% compared to Canopy Growth's net margin of -156.98%. Cabaletta Bio's return on equity of -50.10% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Canopy Growth -156.98%-56.52%-24.18% Do institutionals & insiders believe in CABA or CGC? 3.3% of Canopy Growth shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by company insiders. Comparatively, 1.3% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, CABA or CGC? Cabaletta Bio has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Which has better valuation & earnings, CABA or CGC? Cabaletta Bio has higher earnings, but lower revenue than Canopy Growth. Cabaletta Bio is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.54-0.74Canopy Growth$276.75M1.18-$487.23M-$3.80-0.47 Do analysts rate CABA or CGC? Cabaletta Bio presently has a consensus target price of $20.33, indicating a potential upside of 981.56%. Canopy Growth has a consensus target price of $2.00, indicating a potential upside of 12.99%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the MarketBeat Community prefer CABA or CGC? Cabaletta Bio received 77 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 72.93% of users gave Cabaletta Bio an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9772.93% Underperform Votes3627.07% Canopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% Does the media favor CABA or CGC? In the previous week, Canopy Growth had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 15 mentions for Canopy Growth and 10 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.05 beat Canopy Growth's score of 0.02 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 0 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCabaletta Bio beats Canopy Growth on 13 of the 18 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.40M$2.97B$5.42B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.8731.5826.8320.05Price / SalesN/A429.55393.86117.02Price / CashN/A168.6838.2534.62Price / Book0.343.376.874.61Net Income-$67.68M-$72.17M$3.22B$248.19M7 Day Performance42.42%15.52%5.65%2.88%1 Month Performance70.91%22.04%13.54%15.40%1 Year Performance-85.40%-24.88%18.16%7.68% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.4403 of 5 stars$1.88-2.1%$20.33+981.6%-85.4%$95.40MN/A-0.8750Earnings ReportCGCCanopy Growth1.4244 of 5 stars$1.42+8.0%$2.00+41.3%-82.5%$260.17M$276.75M-0.373,150Trending NewsGap UpALLOAllogene Therapeutics3.6332 of 5 stars$1.18+1.3%$9.29+690.5%-55.2%$256.98M$22,000.00-0.75310Analyst RevisionGap UpLFCRLifecore Biomedical1.2366 of 5 stars$6.93-0.6%$8.00+15.4%+11.7%$256.55M$130.31M-12.37690Gap UpAVIRAtea Pharmaceuticals2.4573 of 5 stars$2.99+9.7%$6.00+101.0%-19.4%$255.03MN/A-1.4470ATXSAstria Therapeutics2.0227 of 5 stars$4.44+5.0%$30.00+575.7%-55.3%$252.26MN/A-2.1430News CoveragePositive NewsGap UpFHTXFoghorn Therapeutics2.689 of 5 stars$4.51+7.3%$12.13+169.1%-31.0%$251.58M$22.60M-2.35120News CoverageEarnings ReportAnalyst RevisionGOSSGossamer Bio3.8326 of 5 stars$1.11-0.5%$7.50+578.7%+72.7%$251.08M$114.70M-3.45180Earnings ReportSLRNAcelyrin3.6239 of 5 stars$2.49+5.3%$9.60+286.3%-47.2%$250.75MN/A-1.01135Positive NewsEarnings ReportAVTEAerovate Therapeutics1.6455 of 5 stars$8.65-3.9%$78.75+810.4%-98.9%$250.72MN/A-2.8920Positive NewsHigh Trading VolumeCADLCandel Therapeutics2.0578 of 5 stars$5.07+5.4%$21.00+314.2%-50.7%$249.80M$120,000.00-2.9360 Related Companies and Tools Related Companies CGC Competitors ALLO Competitors LFCR Competitors AVIR Competitors ATXS Competitors FHTX Competitors GOSS Competitors SLRN Competitors AVTE Competitors CADL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CABA Stock Free CABA Stock Alerts